JAAD onlineDermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib
References (5)
- et al.
BRAF inhibitor unveils its potential against advanced melanoma
Cancer Cell
(2010) - et al.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
N Engl J Med
(2011)
Cited by (13)
BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression
2016, Human PathologyCitation Excerpt :In addition, more than 75% of MN biopsied during BRAFi therapy exhibited histologic atypia (diagnosed as DN or nevus with atypical features). As previously noted by Gerami et al [18], the degree of histologic atypia in BRAFi-MLs was often moderate to severe, and further ancillary studies (HMB45, Mart-1/Ki-67) were performed to further characterize these lesions. We noticed MLs developing on BRAFi that were diagnosed as melanoma tended to be biopsied 5 weeks earlier in BRAFi therapy compared with MLs diagnosed as nevi.
An Amelanotic Dysplastic Melanocytic Nevus Induced by Vemurafenib
2014, Actas Dermo-SifiliograficasAn amelanotic dysplastic melanocytic nevus induced by vemurafenib
2014, Actas Dermo-SifiliograficasMelanoma patients under vemurafenib: Prospective follow-up of melanocytic lesions by digital dermoscopy
2014, Journal of Investigative DermatologyCitation Excerpt :This life-time risk is generally estimated from 1.9% (Bower et al., 2010) to 10.8% (Murali et al., 2012). For some authors, this risk is highest during the first year after surgical treatment of the primary skin lesion, from 4.1% (Hwa et al., 2012) to 6% (Ferrone et al., 2005), and remains high up to 20 years after the first diagnosis (de Giorgi et al., 2012). Compared with these data, SPMs under BRAF inhibitors are likely to be much more frequent and of much earlier onset.
Cutaneous toxicities of new treatments for melanoma
2018, Clinical and Translational Oncology
Disclosure: Dr Gerami has served as a consultant to Abbott Molecular Labs and Neogenomics and has received honoraria for this. This work was supported by the Dermatology Foundation and the American Cancer Society, IL Division (Sponsored Reference Award#: 160272). Dr Martini has served on the advisory board of Dove-Unilever and has received honoraria for this. She has also been an investigator for Melasciences Inc.
Conflicts of interest: None declared.